
    
      This is a phase 1, randomized, double-blind, placebo-controlled, single-and multiple
      ascending dose study. Up to eighty-eight subjects with Systemic Lupus Erythematosus will be
      selected to participate. Subjects will be randomized to receive either ABT-199 or placebo.
      Subjects will be administered ABT-199/placebo as a single dose or up to 14 days as multiple
      doses.
    
  